1. Home
  2. TDF vs SENS Comparison

TDF vs SENS Comparison

Compare TDF & SENS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Templeton Dragon Fund Inc.

TDF

Templeton Dragon Fund Inc.

HOLD

Current Price

$10.96

Market Cap

289.1M

Sector

Finance

ML Signal

HOLD

Logo Senseonics Holdings Inc.

SENS

Senseonics Holdings Inc.

HOLD

Current Price

$6.33

Market Cap

301.2M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
TDF
SENS
Founded
1994
1996
Country
Singapore
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Industrial Machinery/Components
Sector
Finance
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
289.1M
301.2M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
TDF
SENS
Price
$10.96
$6.33
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$18.38
AVG Volume (30 Days)
59.3K
1.2M
Earning Date
01-01-0001
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$16,389,000.00
Revenue This Year
N/A
$74.15
Revenue Next Year
N/A
$58.60
P/E Ratio
N/A
N/A
Revenue Growth
N/A
19.85
52 Week Low
$9.46
$0.41
52 Week High
$12.20
$8.75

Technical Indicators

Market Signals
Indicator
TDF
SENS
Relative Strength Index (RSI) 41.78 54.87
Support Level $10.25 $5.41
Resistance Level $11.48 $8.55
Average True Range (ATR) 0.29 0.47
MACD -0.07 0.10
Stochastic Oscillator 15.86 83.98

Price Performance

Historical Comparison
TDF
SENS

About TDF Templeton Dragon Fund Inc.

Templeton Dragon Fund Inc is a closed-end management investment company. The fund seeks long-term capital appreciation by investing majority of its total assets in equity securities of China companies. It invest in various sectors such as gas & consumable fuels, auto components, banks, beverages, communications equipment, healthcare equipment & supplies, restaurants & leisure, household durables and many others.

About SENS Senseonics Holdings Inc.

Senseonics Holdings Inc is a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Its implantable CGM system, Eversense, including Eversense E3 and Eversense 365 CGM systems, measures glucose levels via an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company operates through one reportable segment which derives its revenues from diabetes products and services and generates the majority of its revenue from the United States.

Share on Social Networks: